Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin PK/PD in Sepsis
NCT02365272Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2012
- Primary completion
- Dec 2014
- Sponsor
- UZ Leuven
- Modality
- Small Molecules
- Drugs
- amikacin
- Conditions
- sepsisseptic shock
01
Overview
Phase 4 trial of amikacin in sepsis and septic shock (2 arms), sponsored by UZ Leuven. Primary endpoint: Number of participants with amikacin PK/PD target attainment. Started Dec 2012; status: completed.
02
Design
2 armsStandard Dose
Amikacin standard dose
Critical Care Dose
Amikacin dose for critical care patients
03
Who it enrols
Adult patients admitted to the ED with severe sepsis or septic shock requiring amikacin, excluding those with burns, pregnancy, recent amikacin use, or allergy to aminoglycosides.
04
Endpoints
Primary
Number of participants with amikacin PK/PD target attainment
Beyond the preview
Go deeper on NCT02365272.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02365272.